| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
- In a screening experiment comparing several astragalosides for their effects on osteoblast differentiation, Isoastragaloside IV (at 40 µM) was tested alongside others (including Astragaloside I-IV and other isoforms). MC3T3-E1 cells were treated with these compounds for 3, 5, or 7 days. Alkaline phosphatase (ALP) activity, an early marker of osteoblast differentiation, was measured. The results indicated that treatment with Isoastragaloside IV did not induce a significant increase in ALP activity compared to the more potent compound Astragaloside I (As-I) under the tested conditions [1].
|
|---|---|
| Cell Assay |
- ALP Activity Screening Assay: MC3T3-E1 pre-osteoblast cells were seeded in 96-well plates and cultured in osteogenic differentiation medium. The cells were treated with various astragalosides, including Isoastragaloside IV, at a concentration of 40 µM for 3, 5, or 7 days. After treatment, the culture medium was removed, and cells were washed and lysed. The ALP activity in the cell lysate was measured using p-nitrophenyl phosphate as a substrate. The reaction was carried out at 37°C for 30 minutes and stopped with NaOH. Absorbance was measured at 405 nm. ALP activity was normalized to the total protein content determined by a bicinchoninic acid (BCA) protein assay [1].
|
| References | |
| Additional Infomation |
It has been reported that Astragalus membranaceus contains isoastragaloside IV and related data have been reported.
- Role of this study: Isastragaloside IV is one of seven astragaloside compounds (astragaloside I-IV, isoastragaloside I, II and IV), which were included in the initial screening to identify the most potent inducers of osteoblast differentiation in MC3T3-E1 cells. The focus of this study was on the most potent astragaloside I (As-I). Isastragaloside IV was mainly used as a control in this screening phase [1]. - Limited data: Apart from testing at a single concentration (40 µM) and time points (3, 5, 7 days) in the initial ALP activity screening, no further data on the bioactivity, mechanism of action or other properties of isastragaloside IV were available in the literature [1]. |
| Molecular Formula |
C41H68O14
|
|---|---|
| Molecular Weight |
784.9702
|
| Exact Mass |
784.46
|
| CAS # |
136033-55-1
|
| PubChem CID |
102393334
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
55
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
O([H])[C@@]1([H])C([H])([H])[C@@]2([H])[C@]3(C([H])([H])[H])C([H])([H])[C@@]([H])([C@]([H])([C@@]4(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(C([H])([H])[H])(C([H])([H])[H])O[C@@]5([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O5)O[H])O[H])O[H])O4)[C@@]3(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]32C([H])([H])[C@]23C([H])([H])C([H])([H])[C@@]([H])(C(C([H])([H])[H])(C([H])([H])[H])[C@@]21[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])(C([H])([H])O1)O[H])O[H])O[H])O[H]
|
| InChi Key |
MSSYPWFHLFBMMP-BQAOMNQWSA-N
|
| InChi Code |
InChI=1S/C41H68O14/c1-35(2)24(53-33-29(49)26(46)21(45)17-51-33)9-11-41-18-40(41)13-12-37(5)32(20(44)15-38(37,6)23(40)14-19(43)31(35)41)39(7)10-8-25(54-39)36(3,4)55-34-30(50)28(48)27(47)22(16-42)52-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20-,21+,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34-,37+,38-,39+,40-,41+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[2-[(2S,5R)-5-[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-9,14-dihydroxy-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-15-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]-5-methyloxolan-2-yl]propan-2-yloxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~63.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3697 mL | 12.7393 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5479 mL | |
| 10 mM | 0.1274 mL | 0.6370 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
